Marshall Financial Group LLC Has $1.61 Million Stock Holdings in Novo Nordisk A/S $NVO

Marshall Financial Group LLC boosted its stake in Novo Nordisk A/S (NYSE:NVO) by 711.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 31,689 shares of the company’s stock after acquiring an additional 27,782 shares during the quarter. Marshall Financial Group LLC’s holdings in Novo Nordisk A/S were worth $1,612,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Revolve Wealth Partners LLC boosted its position in Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after purchasing an additional 200 shares during the last quarter. AQR Capital Management LLC increased its position in Novo Nordisk A/S by 21.0% in the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after purchasing an additional 10,758 shares during the last quarter. Sivia Capital Partners LLC increased its position in Novo Nordisk A/S by 18.2% in the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after purchasing an additional 1,587 shares during the last quarter. Nomura Asset Management Co. Ltd. purchased a new stake in shares of Novo Nordisk A/S during the 2nd quarter worth about $405,000. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at about $75,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Down 1.5%

NYSE:NVO opened at $36.51 on Monday. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The company’s 50 day moving average is $48.22 and its 200-day moving average is $51.07. The firm has a market cap of $163.00 billion, a price-to-earnings ratio of 10.52 and a beta of 0.74. Novo Nordisk A/S has a 12 month low of $35.85 and a 12 month high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be given a dividend of $1.2751 per share. This represents a dividend yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s payout ratio is currently 23.63%.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approves higher‑dose Wegovy (semaglutide 7.2 mg, “Wegovy HD”) with strong STEP UP trial weight‑loss results (~20.7% mean weight loss); company plans a U.S. launch in April—this supports revenue and market share recovery vs. Lilly. Reuters: Novo Nordisk wins U.S. nod for higher-dose Wegovy
• Positive Sentiment: Chinese government official expressed support for Novo Nordisk’s continued presence and market cultivation in China—political goodwill could ease market access and reimbursement discussions in a major growth market. Reuters: China expresses hopes over Novo Nordisk’s presence in market
• Neutral Sentiment: Sanford C. Bernstein initiated coverage on NVO — could increase analyst attention and liquidity; impact depends on the firm’s stance and ratings (article linked). Sanford C. Bernstein Initiates Coverage on Novo Nordisk
• Neutral Sentiment: Rhythm Pharmaceuticals won an FDA approval for a rare genetic‑obesity therapy—limited overlap with Novo’s mass‑market GLP‑1 franchise, so competitive impact is minimal. Yahoo/Finance: Rhythm Grabs A New Obesity Approval
• Negative Sentiment: An FDA warning letter flagged deficiencies in Novo’s pharmacovigilance reporting for serious/unexpected adverse events for GLP‑1s (including Ozempic/Wegovy)—this raises regulatory scrutiny and potential compliance costs, which investors view negatively. Yahoo/Finance: FDA Letter Puts Novo Nordisk GLP-1 Risks And Valuation In Focus
• Negative Sentiment: Patent expiry for semaglutide in India opens the market to low‑cost generics (reports of Ozempic copies selling for ~$14) — this threatens international pricing and volume, particularly in large emerging markets. Financial Post: Ozempic Copies to Cost $14 in India
• Negative Sentiment: Competitive pressure from Eli Lilly’s next‑gen agents (retatrutide) and positive data for rivals are keeping investor concerns about market share and pricing intensity elevated. ProactiveInvestors: Lilly GLP-1 trial data and concerns
• Negative Sentiment: Semaglutide failed to show benefit in early Alzheimer’s at AD/PD 2026—this is a setback for potential label expansion beyond metabolic indications and reduces upside from new indications. Yahoo News: AD/PD 2026: semaglutide fails in early Alzheimer’s

Analyst Ratings Changes

Several brokerages recently commented on NVO. Kepler Capital Markets cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. CICC Research initiated coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They issued an “outperform” rating and a $73.50 target price for the company. HSBC restated a “hold” rating and set a $54.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Finally, Morgan Stanley raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price objective for the company in a research note on Tuesday, March 3rd. Four investment analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.